At Lilly, we value partnerships. Through working together, we can discover, develop, and deliver the innovative pharmaceutical therapies that will help people live longer, healthier, and more active lives. Lilly is committed to working with Europe-based patient advocacy organisations for the benefit of patients in a way that is true to the EFPIA Code of Practice and Lilly's integrity in business policy. Lilly takes its commitment to transparency seriously. Since 2009, we have published an annual register of Europe-based patient groups that have received either financial or significant non-financial support from Lilly.
Several of our affiliates in Europe also publish national registers relating to support given to patient organisations in their country. Please be aware that the format and timing of this data disclosure may vary depending on local laws and regulations.
Eli Lilly and Company's disclosure of its support to patient organisations is one of the activities undertaken by the Company to improve transparency concerning Company dealings with third parties. Most of the data had to be compiled manually across a number of legal entities and countries. Eli Lilly and Company herein declares that the Company has made its best efforts to make a comprehensive disclosure of concerned activities.
|Patient Organisation Disclosure Report|
* There has been no support to Patient Organisations in this country during this year.
Reports from previous years: